HLA-B and neoplasm: The original study reported that in tumor samples, post-treatment expression of HLA-B was significantly downregulated, suggesting a specific immunologic pressure exerted by the immune system on HLA-B, particularly from the HLA-B*35:02-restricted CD8 + T cells that were transferred as part of the treatment [20].